Key Highlights
- Strategic tie-up leverages OBI’s GlycOBI® ADC platform with TegMine’s glycan-targeting antibody discovery system, TegMiner™, to unlock next-gen oncology drugs
- Deal structure includes Master Services Agreement with pathway to licensing, potentially fast-tracking multiple ADC candidates to clinical pipelines
- Combines tumor-specific targeting with site-specific conjugation, aiming for superior efficacy, safety, and manufacturability of ADCs
1. Powering the Next-Gen ADC Revolution: OBI’s GlycOBI® Meets TegMine’s TegMiner™
The collaboration between Taiwan-based OBI Pharma and US-based TegMine Therapeutics introduces a fusion of two advanced oncology technologies. OBI’s proprietary GlycOBI® ADC platform—engineered to deliver site-specific, homogenous antibody-drug conjugates—will be combined with TegMine’s TegMiner™, a platform focused on tumor-specific glycans and glycoproteins. Together, they aim to generate ADCs with heightened tumor selectivity and minimized off-target toxicity. The GlycOBI® format’s ‘Plug and Play’ adaptability allows for integration with a variety of antibodies and payloads, positioning this partnership to scale rapidly.
2. Strategic Agreement Designed for Acceleration and Impact
Signed as a Master Services Agreement (MSA), the partnership grants TegMine access to OBI’s ADC technology, including EndoSymeOBI® and HYPrOBI™, to identify and co-develop ADC candidates. If successful, both parties will enter a licensing agreement for further clinical development. This tiered model supports quick experimentation and clear commercialization pathways, particularly beneficial in the fast-evolving ADC landscape.
3. Innovation Synergy for Unmet Oncology Needs
Both companies share a mission to address hard-to-treat cancers using differentiated, biology-first approaches. OBI brings deep clinical-stage experience and a growing pipeline including OBI-992 and OBI-902, while TegMine’s antibody discovery engine is unlocking novel glycan targets rarely present in healthy tissue. This synergy is poised to push boundaries in ADC development—potentially bringing highly selective and efficacious therapeutics to patients with limited options.
4. Platform Expansion and Global Biopharma Relevance
The collaboration further validates GlycOBI®’s industry relevance as a licensable technology platform, not just a proprietary pipeline tool. For TegMine, the deal accelerates translation of glycan-focused discovery into tangible clinical programs. As global biopharma increasingly shifts toward platform-centric, plug-and-play innovation in oncology, this partnership stands as a strategic example of how specialized tools can integrate to create scalable, next-gen treatment modalities.
For more information, visit:
OBI Pharma | TegMine Therapeutics
By
